Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of faricimab in myopic choroidal neovascularization secondary to pathologic myopia
CTR20240107Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of faricimab in Subretinal neovascularization, sponsored by Roche. Started Mar 2024; status: completed.
02
Drugs
faricimab
03
Conditions
Subretinal neovascularization
Beyond the preview
Go deeper on CTR20240107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240107.